AI Article Synopsis
- The study assessed the effectiveness of a quadruple therapy consisting of furazolidone, amoxicillin, bismuth, and a proton pump inhibitor for treating a specific infection, with a focus on understanding factors that might lead to treatment failure.
- Out of 992 patients treated, the therapy achieved a high overall eradication rate of 94.5%, with slightly different rates for primary (95.0%) and rescue treatments (91.3%).
- Key predictors for failed eradication included poor medication adherence, having undergone two or more previous treatments, and alcohol consumption during therapy, suggesting that addressing these issues could enhance treatment success.
Article Abstract
Aim: To evaluate the outcomes of furazolidone- and amoxicillin-based quadruple therapy for treatment of () infection and identify predictors of failed eradication.
Methods: Patients with infection treated with furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January 2015 to December 2015) who received the C-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior treatment attempts, medication adherence, alcohol and cigarette consumption during therapy, and treatment-related adverse events were recorded by reviewing medical records and telephone surveys. eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed eradication.
Results: Of the 992 patients treated and retested for infection, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. eradication rate of primary therapy was 95.0% (95%CI: 93.5%-96.5%), while that of rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. On multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], two or more previous treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed eradication.
Conclusion: Furazolidone- and amoxicillin-based quadruple therapy for infection in an area with a high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize eradication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209572 | PMC |
| http://dx.doi.org/10.3748/wjg.v24.i40.4596 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and predictors of poor heart failure treatment outcomes in Ethiopia: a systematic review and meta-analysis.
Front Cardiovasc Med
December 2024
Department of Pharmacy, Institute of Health Science, Wallaga University, Nekemte, Ethiopia.
Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Various factors can exacerbate disease progression in patients with HF and negatively impact treatment outcomes. This study aims to evaluate the pooled prevalence and contributing factors associated with poor heart failure treatment outcomes in Ethiopia.
View Article and Find Full Text PDFBehavioral and biomedical factors associated with lifestyle modification practices among diagnosed hypertensive patients in pastoral health facilities of southern Ethiopia.
Front Cardiovasc Med
December 2024
School of Public Health, College of Health Science and Medicine, Wolaita Sodo University, Sodo, Ethiopia.
Background: More than 23 million deaths and 36.5% of disability-adjusted life-years are the result of the direct effects of unhealthy behavior alone. Daily behaviors have strong implications for health outcomes and quality of life.
View Article and Find Full Text PDFBackground And Objectives: Generic formulations of glatiramer acetate have been available since 2015 yet remain underprescribed relative to the branded product. We sought to characterize the association between branded glatiramer prescribing in the Medicare program and financial payments from the manufacturer (Teva Pharmaceuticals).
Methods: Using publicly available Medicare Part D and Open Payments data from the Centers for Medicare and Medicaid Services, we evaluated overall utilization from 2012 to 2021 and compared the prevalence, frequency, and magnitude of financial payments made in 2019 to neurologists who prescribed branded and generic versions of glatiramer in 2020.
Magnitude and factors associated with low birth weight among newborns in public health facilities of Mekelle City, northern Ethiopia: a multi-center study.
Front Pediatr
December 2024
Department of Midwifery, College of Medicine and Health Sciences, Adigrat University, Adigrat, Ethiopia.
Background: Low birth weight is a key determinant of child survival, significantly influencing rates of infant and childhood mortality, morbidity, and disability. While some studies have been conducted in our region, there is still a gap in evidence regarding the maternal characteristics associated with low birth weight. Hence, this study aimed to determine the proportion of newborns with low birth weight and determinant factors, particularly focusing on maternal characteristics.
View Article and Find Full Text PDFCaregiving responsibility and psychological distress among community-dwelling cancer survivors in the United States.
Support Care Cancer
January 2025
Department of Communication and Film, the University of Memphis, Memphis, TN, USA.
Purpose: There are over 18 million cancer survivors in the U.S., with a projected increase of 24.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!